1. Home
  2. SCM vs MYGN Comparison

SCM vs MYGN Comparison

Compare SCM & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCM
  • MYGN
  • Stock Information
  • Founded
  • SCM 2012
  • MYGN 1991
  • Country
  • SCM United States
  • MYGN United States
  • Employees
  • SCM N/A
  • MYGN N/A
  • Industry
  • SCM Finance/Investors Services
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • SCM Finance
  • MYGN Health Care
  • Exchange
  • SCM Nasdaq
  • MYGN Nasdaq
  • Market Cap
  • SCM 412.9M
  • MYGN 423.1M
  • IPO Year
  • SCM 2012
  • MYGN 1995
  • Fundamental
  • Price
  • SCM $14.53
  • MYGN $6.37
  • Analyst Decision
  • SCM Hold
  • MYGN Hold
  • Analyst Count
  • SCM 1
  • MYGN 13
  • Target Price
  • SCM $13.00
  • MYGN $13.50
  • AVG Volume (30 Days)
  • SCM 150.2K
  • MYGN 2.4M
  • Earning Date
  • SCM 08-06-2025
  • MYGN 08-05-2025
  • Dividend Yield
  • SCM 11.01%
  • MYGN N/A
  • EPS Growth
  • SCM 11.71
  • MYGN N/A
  • EPS
  • SCM 1.43
  • MYGN N/A
  • Revenue
  • SCM $102,761,445.00
  • MYGN $832,900,000.00
  • Revenue This Year
  • SCM N/A
  • MYGN $0.17
  • Revenue Next Year
  • SCM $1.23
  • MYGN $6.19
  • P/E Ratio
  • SCM $10.13
  • MYGN N/A
  • Revenue Growth
  • SCM N/A
  • MYGN 3.83
  • 52 Week Low
  • SCM $11.19
  • MYGN $3.76
  • 52 Week High
  • SCM $15.56
  • MYGN $29.30
  • Technical
  • Relative Strength Index (RSI)
  • SCM 51.05
  • MYGN 66.01
  • Support Level
  • SCM $14.35
  • MYGN $5.78
  • Resistance Level
  • SCM $14.77
  • MYGN $6.06
  • Average True Range (ATR)
  • SCM 0.20
  • MYGN 0.30
  • MACD
  • SCM -0.00
  • MYGN 0.05
  • Stochastic Oscillator
  • SCM 36.73
  • MYGN 85.71

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Share on Social Networks: